The goal of this program is to improve population health by assisting clinicians and their patients to address the challenges of individualizing breast cancer treatment for women with favorable prognosis. Project 1 is concerned with the management of locoregional therapy;Project 2 with the management of systemic therapy;and Project 3 aims to evaluate a Patient Intervention decision tool. Common elements across projects include being informed by an overall conceptual model, presenting similar constructs, and sharing a methodology requiring the use of patient surveys, and the merging of -Surveillance, Epidemiology and End Results (SEER) Registry clinical data elements with information obtained from patient surveys. Finally, Projects 1 and 2 propose surveying attending clinicians of patient participants. Core B will support these cross-project activities by: overseeing the development and use of consistent survey measures, maximizing the efficiency of a uniform strategy for SEER-based sampling and rapid case ascertainment;coordinating patient and clinician survey data collection protocols;and, developing standardized methods for merging datasets. This Core will have an opportunity to advance innovative population-based methods regarding measurement reliability, validity, and durability.
The specific aims of Core B are as follows:
Aim 1 : Develop a bank of survey measures and items that will provide consistency in the measurement of common constructs across studies.
Aim 2 : Develop and implement a uniform strategy for SEER-based sampling, rapid case ascertainment, and the integration of clinical data collected through routine surveillance activities.
Aim 3 : Coordinate the development and implementation of patient and clinician surveys to maximize participant rates, minimize the number of unique patients required across studies, and minimize the administrative burden on SEER sites.
Aim 4 : Validate key clinical information collected by SEER under the new SEER 2010 data requirements against patient self-report (e.g., receipt of radiation) and other objective measures (e.g., 21 gene assay).
Aim 5 : Further inform our measurement of

Public Health Relevance

Results from this program will improve public health by addressing the challenges of individualizing care for women with breast cancer. This Core will focus on advancing innovative methods in population-based cancer research by sun/eying large numbers of patients and their clinicians across three distinct areas of the United States and assessing the validity of clinical measures important in cancer quality of care research

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA163233-01A1
Application #
8374179
Study Section
Special Emphasis Panel (ZCA1-RPRB-B (M1))
Project Start
2012-09-01
Project End
2017-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
1
Fiscal Year
2012
Total Cost
$1,141,690
Indirect Cost
$141,252
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Katz, Steven J; Hawley, Sarah T; Hamilton, Ann S et al. (2018) Surgeon Influence on Variation in Receipt of Contralateral Prophylactic Mastectomy for Women With Breast Cancer. JAMA Surg 153:29-36
Lee, Kamaria L; Janz, Nancy K; Zikmund-Fisher, Brian J et al. (2018) What Factors Influence Women's Perceptions of their Systemic Recurrence Risk after Breast Cancer Treatment? Med Decis Making 38:95-106
Morrow, Monica; Jagsi, Reshma; McLeod, M Chandler et al. (2018) Surgeon Attitudes Toward the Omission of Axillary Dissection in Early Breast Cancer. JAMA Oncol 4:1511-1516
Radhakrishnan, Archana; Chandler McLeod, M; Hamilton, Ann S et al. (2018) Preferences for Physician Roles in Follow-up Care During Survivorship: Do Patients, Primary Care Providers, and Oncologists Agree? J Gen Intern Med :
Jagsi, Reshma; Ward, Kevin C; Abrahamse, Paul H et al. (2018) Unmet need for clinician engagement regarding financial toxicity after diagnosis of breast cancer. Cancer 124:3668-3676
Kurian, Allison W; Ward, Kevin C; Hamilton, Ann S et al. (2018) Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer. JAMA Oncol 4:1066-1072
Resnicow, Ken; Patel, Minal R; Mcleod, M Chandler et al. (2018) Physician attitudes about cost consciousness for breast cancer treatment: differences by cancer sub-specialty. Breast Cancer Res Treat :
Katz, Steven J; Bondarenko, Irina; Ward, Kevin C et al. (2018) Association of Attending Surgeon With Variation in the Receipt of Genetic Testing After Diagnosis of Breast Cancer. JAMA Surg 153:909-916
Morrow, Monica; Abrahamse, Paul; Katz, Steven J (2018) Trend Analysis on Reoperation After Lumpectomy for Breast Cancer-Reply. JAMA Oncol 4:747
Gornick, Michele C; Kurian, Allison W; An, Lawrence C et al. (2018) Knowledge regarding and patterns of genetic testing in patients newly diagnosed with breast cancer participating in the iCanDecide trial. Cancer 124:4000-4009

Showing the most recent 10 out of 47 publications